CYP21A2 and congenital adrenal hyperplasia: Interestingly, CAH patients with severe mutations in the CYP21A2 gene (Null/Null and Null/A genotypes) in our study were significantly leaner and had more favorable lipid profiles compared with less severe mutations, resulting in higher residual 21OHP activity.